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hepatic decompensation. Our results demonstrate the long-term anti-fibrotic benefits 
associated with PrOD therapy for chronic HCV.
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Background. The high cost of direct-acting antiviral agents (DAAs) for hepatitis 
C virus (HCV) infection may present a barrier to access, thus contributing to dispar-
ities in treatment. However, few real-world data exist on factors associated with DAA 
uptake.
Methods. We conducted an observational study of Kaiser Permanente Northern 
California members with HCV infection, defined as a positive HCV RNA test or an 
HCV genotype, during the recent DAA era (i.e., October 2014–December 2016). To 
evaluate factors independently associated with DAA initiation, an adjusted Poisson 
model included age, sex, race/ethnicity, census-based neighborhood deprivation 
index, HCV genotype, advanced fibrosis (i.e., Fibroscan ≥9.5 kPa, if available; else 
FIB-4 >3.25), prior HCV treatment, drug abuse diagnosis, smoking, alcoholic drinks 
per week, HIV infection, and hepatitis B virus infection.
Results. We identified 18,140 HCV-infected individuals, of whom 6167 (34%) 
initiated DAA treatment. Treatment was less likely among Black (risk ratio [RR] 
0.83, 95% confidence interval [CI]: 0.79-0.88) and Hispanic individuals (RR 0.92, 
95% CI: 0.87-0.98) compared with White individuals, and among individuals with 
greater neighborhood-level economic disadvantage (quartile 3 vs. 1: RR 0.89, 95% CI: 
0.85-0.94; quartile 4 vs. 1: RR 0.79, 95% CI: 0.75-0.83). Treatment was also less likely 
among those with a history of drug abuse (RR 0.87, 95% CI: 0.82-0.91), smoking (RR 
0.84, 95% CI: 0.80-0.87), or more alcoholic drinks per week (1–7 vs. 0 drinks: RR 0.88, 
95% CI: 0.82-0.93; 8-16 vs. 0 drinks: RR 0.72, 0.63-0.82); ≥17 vs. 0 drinks: RR 0.63, 
95% CI: 0.49-0.80). There was a higher likelihood of treatment among individuals with 
advanced fibrosis (RR 1.39, 95% CI: 1.34-1.44), HCV genotype 1 (RR 1.97, 95% CI: 
1.87-2.08), no prior HCV treatment (RR 1.44, 95% CI: 1.37-1.52), or HIV infection 
(RR 1.19, 95% CI: 1.08-1.30).
Conclusion. Although clinical factors appear to drive HCV treatment decisions, 
racial/ethnic and socioeconomic disparities exist in DAA uptake. Lifestyle factors, such 
as alcohol use and drug abuse, may also influence patient or provider decision-making 
regarding DAA initiation. Strategies are needed to ensure equitable access to DAAs, 
even in insured populations.
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Background. New cases of Hepatitis C virus (HCV) infection are climbing in 
young adults and particularly in women of child-bearing age. Despite this growing 
burden, a risk-based screening approach is still recommended when testing for HCV 
in pregnant women and young adults. Risk-based screening was abandoned for “Baby 
Boomer” adults in favor of universal screening due to concerns for insufficient capture 
of cases.
Objective. We analyzed public health department data for all 50 states to compare 
the published rates of HCV infection among young adults and Baby Boomers
Methods. Public health department websites for all 50 states were reviewed for 
the most recent information on HCV incidence and prevalence. Age-specific rates 
were recorded for young adults (ages 20–39) compared with Baby Boomers (ages 
50–70). When specific rates were not available, data on year over year trends were 
noted for both age groups.
Results. Using their own published data, we identified 11 states where rates of 
HCV infection in young adults surpassed that of Baby Boomers, and 4 states where the 
rates of HCV were equal between the 2 age groups. These states alone make-up 25% of 
the entire US population. When we include 6 additional highly populous states with 
reported HCV incidence on the rise in young adults, these 21 states account for more 
than half the US population. Only 4 states reported HCV rates in Baby Boomers to be 
higher than young adults and 25 states had no recent data to review. Of note, most of 
these states are direct neighbors to states in the first 2 categories with a higher burden 
of HCV.
Conclusion. Even using a risk-based screening strategy with lower case capture 
rate in young adults compared with universal screening in Baby Boomers, we identified 
that many states have HCV rates in young adults that is as high or higher than Baby 
Boomers. These results suggest that universal screening in this age group is warranted, 
where DAA treatment could reduce future spread. Pregnant women represent an easy 
group to target given their frequent medical visits, frequent lab testing, their exposed 
infants would require follow-up testing and the women could be referred for DAA 
treatment after delivery.
Disclosures. R. Jhaveri, Gilead: Grant Investigator, Grant recipient. Abbvie: 
Grant Investigator, Grant recipient. Merck: Grant Investigator, Grant recipient 
526. Is DAA Treatment Associated with HBV Reactivation? Results from 
ERCHIVES
Adeel Butt, MD, MS1; Peng Yan, MS2; Obaid Shaikh, MD3 and Abdul-Badi Abou-
Samra, MD, PhD4; 1Weill Cornell Medical College, New York, New York, 2VA 
Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, 3Univesity of Pittsburgh, 
Pittsburgh, Pennsylvania, 4Hamad Medical Corporation, Doha, Qatar 
Session: 59. Hepatitis B and C in Varied Settings
Thursday, October 5, 2017: 12:30 PM      
Background. Reactivation of HBV infection has been reported in patients with 
HCV treated with newer directly acting antiviral agents (DAAs). Magnitude of this 
problem and its consequences are not fully understood.
Methods. Using ERCHIVES, a well-established national database of HCV 
infected Veterans, we identified all persons who received DAA treatment for 
>28 days. We determined the proportion of patients who had HBV viral reactiva-
tion (≥1 log10 increase in HBV DNA from baseline), seroconversion (from HBsAg 
